To address this, integrating multidimensional biomarkers—such as indicators reflecting the abnormal metabolism of Aβ, hyperphosphorylation of tau protein, and damage to the neurovascular unit—can facilitate the creation of a dedicated AD “diagnostic fingerprint” that accurately eliminates “false positive” interference. This evidence concerns the gene MAPT and Alzheimer disease.